Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature

被引：2

作者：

Baksh, Mizba ^{[1
]}

Jiang, Liuyan ^{[2
]}

Bhatia, Unnati ^{[1
]}

Alegria, Victoria ^{[1
]}

Sher, Taimur ^{[1
]}

Roy, Vivek ^{[1
]}

Chanan-Khan, Asher ^{[1
,3
,4
]}

Ailawadhi, Sikander ^{[1
,3
]}

Parrondo, Ricardo D. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol Oncol, 4500 San Pablo Rd S,Mangurian Bldg,3rd Floor, Jacksonville, FL 32224 USA

[2] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA

[3] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA

[4] St Vincents Riverside, Hematol Oncol, Jacksonville, FL USA

来源：

CLINICAL CASE REPORTS | 2021年 / 9卷 / 12期

关键词：

IgM myeloma; lymphoplasmacytic lymphoma; lytic bone lesions; multiple myeloma; non-Hodgkin's lymphoma; Waldenstrom macroglobulinemia; SMALL LYMPHOCYTIC LYMPHOMA; IGM MULTIPLE-MYELOMA; WALDENSTROMS MACROGLOBULINEMIA; INTERNATIONAL WORKSHOP; TREATMENT RECOMMENDATIONS; OPEN-LABEL; RITUXIMAB; IBRUTINIB; DEXAMETHASONE; MULTICENTER;

D O I：

10.1002/ccr3.5181

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Waldenstrom macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood. We describe a case of an 81-year-old woman with LPL who presented with LBL and was successfully treated with chemoimmunotherapy.

引用

页数：8

共 48 条

[1] Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 [J].

Anderson, G ;

Gries, M ;

Kurihara, N ;

Honjo, T ;

Anderson, J ;

Donnenberg, V ;

Donnenberg, A ;

Ghobrial, I ;

Mapara, MY ;

Stirling, D ;

Roodman, D ;

Lentzsch, S .

BLOOD, 2006, 107 (08) :3098-3105

[2] Multiple myeloma: Clinical review and diagnostic imaging [J].

Angtuaco, EJC ;

Fassas, ABT ;

Walker, R ;

Sethi, R ;

Barlogie, B .

RADIOLOGY, 2004, 231 (01) :11-23

[3] 14q32 translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinernia [J].

Avet-Loiseau, H ;

Garand, R ;

Lodé, L ;

Robillard, N ;

Bataille, R .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :153-155

[4] Extramedullary Waldenstrom macroglobulinemia [J].

Banwait, Ranjit ;

Aljawai, Yosra ;

Cappuccio, Joseph ;

McDiarmid, Serena ;

Morgan, Elizabeth A. ;

Leblebjian, Houry ;

Roccaro, Aldo M. ;

Laubach, Jacob ;

Castillo, Jorge J. ;

Paba-Prada, Claudia ;

Treon, Steven ;

Redd, Robert ;

Weller, Edie ;

Ghobrial, Irene M. .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (02) :100-104

[5] Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia in Waldenstrom's Macroglobulinemia [J].

Berentsen, Sigbjorn .

CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (01) :110-112

[6] Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity [J].

Bonilla-Valentin, Fernando Javier ;

Cerra, Javier ;

Caceres-Perkins, William ;

Alsina, Melissa .

CANCER CONTROL, 2018, 25 (01) :1-4

[7] Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma [J].

Breitkreutz, I. ;

Raab, M. S. ;

Vallet, S. ;

Hideshima, T. ;

Raje, N. ;

Mitsiades, C. ;

Chauhan, D. ;

Okawa, Y. ;

Munshi, N. C. ;

Richardson, P. G. ;

Anderson, K. C. .

LEUKEMIA, 2008, 22 (10) :1925-1932

[8] The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications [J].

Campo, Elias ;

Swerdlow, Steven H. ;

Harris, Nancy L. ;

Pileri, Stefano ;

Stein, Harald ;

Jaffe, Elaine S. .

BLOOD, 2011, 117 (19) :5019-5032

[9]

Castillo JJ, 2020, LANCET HAEMATOL, V7, pE827, DOI 10.1016/S2352-3026(20)30224-6

[10] What is new in the treatment of Waldenstrom macroglobulinemia? [J].

Castillo, Jorge J. ;

Treon, Steven P. .

LEUKEMIA, 2019, 33 (11) :2555-2562

← 1 2 3 4 5 →